HIV-1 Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about HIV-1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting
Phase 1

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

HIV-1-infection
BioNTech SE61 enrolled3 locationsNCT07392372
Recruiting
Phase 4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection
Gilead Sciences350 enrolled14 locationsNCT06337032
Recruiting
Not Applicable

#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

HIV InfectionHIVStigma+3 more
Casper Rokx5,200 enrolled28 locationsNCT06900829
Recruiting
Phase 1

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

HIV-1-infection
Gilead Sciences16 enrolled7 locationsNCT07055451
Recruiting

Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States

HIV-1-infectionPregnancy RelatedBreastfeeding
International Maternal Pediatric Adolescent AIDS Clinical Trials Group1,150 enrolled11 locationsNCT07293559
Recruiting
Early Phase 1

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

HIV-1
City of Hope Medical Center15 enrolled2 locationsNCT06252402
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled24 locationsNCT07266831
Recruiting
Phase 2

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

HIV-1-infection
TaiMed Biologics Inc.75 enrolled11 locationsNCT07215468
Recruiting
Phase 1Phase 2

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection
National Institute of Allergy and Infectious Diseases (NIAID)36 enrolled12 locationsNCT06071767
Recruiting
Not Applicable

Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)

DepressionInflammationHIV-1-infection
Florida International University150 enrolled2 locationsNCT05136703
Recruiting
Not Applicable

Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers

HIV-1-infectionAlcohol Drinking
Syracuse University300 enrolled1 locationNCT06648629
Recruiting
Phase 1

Safety Study of MucoCept-CVN

HIV-1-infection
Craig Cohen, MD, MPH12 enrolled1 locationNCT07181486
Recruiting
Phase 2

A Phase Ⅱa Clinical Study of CL-197 Capsules

HIV-1-infection
Henan Genuine Biotech Co., Ltd.24 enrolled1 locationNCT07308782
Recruiting
Early Phase 1

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

HIV-1-infection
University of California, San Diego138 enrolled1 locationNCT04883255
Recruiting
Phase 2

Improving Coronary Vascular Health in Women

Metabolic DiseaseHIV-1-infectionCoronary Microvascular Dysfunction
Massachusetts General Hospital80 enrolled1 locationNCT06843902
Recruiting

Prevention ICONA Dedicated Ensemble

HIV-1-infectionHIVPrEP+3 more
Fondazione ICONA5,000 enrolled53 locationsNCT07186244
Recruiting
Phase 4

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

HIVHIV-1
UBATEC50 enrolled1 locationNCT06967753
Recruiting
Phase 3

Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

HIV-1-infection
University of Nairobi392 enrolled9 locationsNCT06747507
Recruiting

Investigating the Optimal Management of Dolutegravir Resistance

HIV-1-infection
University of Nairobi6,600 enrolled9 locationsNCT06762054
Recruiting
Phase 2

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

FrailtyAgingHIV-1-infection+2 more
Massachusetts General Hospital100 enrolled2 locationsNCT06554717